Filtered By:
Education: Study
Therapy: Hormonal Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 132 results found since Jan 2013.

Testosterone Treatments Aren ’ t Linked to Heart Risks When Patients Are Carefully Monitored, Study Finds
Advertisements for treatments for “low T,” or low testosterone levels in middle-aged and older men, have led to spikes in demand. But the safety and legitimacy of those testosterone therapies hasn’t been clear. In a new study published in the New England Journal of Medicine and presented at the Endocrine Society’s annual meeting, researchers provide the most conclusive evidence yet that testosterone treatments appear to be safe for the heart and are not associated with an increased risk of certain heart-related events. In the study, led by researchers at the Cleveland Clinic, more than 5,200 men age...
Source: TIME: Health - June 16, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news

Cancers, Vol. 15, Pages 2316: Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
K. Kelly Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, ...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Tags: Review Source Type: research

Hormones for Gender Dysphoria Associated With Cardiovascular Risk Hormones for Gender Dysphoria Associated With Cardiovascular Risk
Largest study to date examining risks of gender-affirming hormone therapy finds increased risks for some cardiovascular events, including notably stroke and heart attack.Medscape Medical News
Source: Medscape Cardiology Headlines - March 10, 2023 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Longer oestrogen exposure could slash the risk of having a stroke, study suggests
The findings suggest that extending oestrogen exposure with hormone therapy could reduce the risk of stroke.
Source: Daily Express - Health - February 2, 2023 Category: Consumer Health News Source Type: news

The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research

Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study
Estrogen therapy is prescribed for women without a uterus. For women with intact uteri, progestogens should be added to protect against endometrial hyperplasia. Different estrogen profiles may cause different side effects and beneficial clinical outcomes [1]. Different forms of estrogen also have different serum E2 concentrations; a previous study demonstrated that 1  mg E2 was equivalent to 0.4 mg CEE [1]. Progestin includes medroxyprogesterone acetate (MPA) and norethindrone acetate (NE). In Taiwan, the most common MHT for patients with an intact uterus are CEE (0.625 mg) or E2 (2 mg) combined with 5 mg MPA or 1 mg NE [2,3].
Source: Maturitas - August 1, 2022 Category: Primary Care Authors: Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding Tags: Original article Source Type: research

Sex and Gender Considerations in Episodic Migraine
AbstractPurpose of ReviewWe seek to update readers on recent advances in our understanding of sex and gender in episodic migraine with a two part series. In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episodic migraine by addressing menstrual migraine and the controversial topic of hormone-containing therapies. We make note of data applicable to gender minority populations, when available, and summarize kn...
Source: Current Pain and Headache Reports - June 9, 2022 Category: Neurology Source Type: research

Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women
CONCLUSIONS: MHT is associated with statistically reduced CVD risk among white but not black women with PreDM or DM. Race is an effect modifier in the association between MHT use and CVD.PMID:35114556 | DOI:10.1016/j.atherosclerosis.2022.01.016
Source: Atherosclerosis - February 3, 2022 Category: Cardiology Authors: Yilin Yoshida Zhipeng Chen Robin L Baudier Marie Krousel-Wood Amanda H Anderson Vivian A Fonseca Franck Mauvais-Jarvis Source Type: research

The impact of micronized progesterone on cardiovascular events - a systematic review
In conclusion, while available data suggest that MP as a component in combined MHT may have a neutral effect on the vascular system, more RCTs investigating the impact of MP alone or in combined MHT on vascular primary endpoints are needed.PMID:35112635 | DOI:10.1080/13697137.2021.2022644
Source: Climacteric - February 3, 2022 Category: Geriatrics Authors: L M Kaemmle A Stadler H Janka M von Wolff P Stute Source Type: research

Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
AbstractBACKGROUNDMenopausal symptoms can be very distressing and considerably affect a woman ’s personal and social life. It is becoming more and more evident that leaving bothersome symptoms untreated in midlife may lead to altered quality of life, reduced work productivity and, possibly, overall impaired health. Hormone therapy (HT) for the relief of menopausal symptoms has been the obj ect of much controversy over the past two decades. At the beginning of the century, a shadow was cast on the use of HT owing to the concern for cardiovascular and cerebrovascular risks, and breast cancer, arising following publication ...
Source: Human Reproduction Update - August 25, 2021 Category: OBGYN Source Type: research

Thyroid Hormone Therapy and Incident Stroke
CONCLUSIONS: Both exogenous hyper- and hypothyroidism were associated with increased risk of stroke, highlighting the importance of patient medication safety.PMID:34137866 | DOI:10.1210/clinem/dgab444
Source: The Journal of Clinical Endocrinology and Metabolism - June 17, 2021 Category: Endocrinology Authors: Maria Papaleontiou Deborah A Levine David Reyes-Gastelum Sarah T Hawley Mousumi Banerjee Megan R Haymart Source Type: research